STEVEN M. CROFT, M.D.; MARK P. JARRETT, M.D.; EDWARD L. SNYDER, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: We read with interest the report by Siber and associates (1) and wish to report our experience that corroborates their findings. In order to investigate the in-vivo immune response in systemic lupus erythematosus, 18 patients were immunized with the pneumococcal vaccine Pneumovax (Lot 2045D, Merck, Sharp and Dohme, West Point, Pennsylvania). Seven healthy volunteers were also immunized, and eight non-immunized patients with systemic lupus erythematosus served as controls. Sera were collected at the time of vaccination and 4 to 6 weeks after immunization. In view of previous reports (2, 3) we assayed the serum samples for anti-A
CROFT SM, JARRETT MP, SNYDER EL. Blood-Group-A-like Substances in Pneumococcal Vaccine. Ann Intern Med. 1982;97:284. doi: 10.7326/0003-4819-97-2-284_2
Download citation file:
Published: Ann Intern Med. 1982;97(2):284.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use